RE:Wondering Here’s my wild guess.
A deal and a listing on the Nasdaq lead by house 65, Goldman.
All those presentations in NYC were for a reason.
Goldman would want to introduce TH at an attractive price for US investors...hence the pounding.
bfw
SPCEO1 wrote: I find it odd that we have not had a corporate presentation update since July nor have we had any analysts comments about anything regarding TH from the analysts during its recent slide. Could there be a big announcement looming and that is why there is so much silence? Why update the corporate presentation if it is just going to need a major revamp soon anyway? Just me speculating based on some very sparse datapoints.
If I had to guess about a big announcement that perhaps the analysts are aware of and sworn to secrecy about, it would be an acquisition. Maybe there is something bigger than we might expect going on and the brokers are all vying for the job of financing it. Ideally, TH would acquire a legacy drug that has approval in the US and Europe and brings along some marketing infrastructure in Europe as well, but that might be asking for too much.
Maybe something meaningful is happening on the Taimed front. They talked openly about gaining access to TMB 365 on the conference call so perhaps there are discussions going on about that and/or other things between the two companies.
There is a lot going on at the company right now, We are stille arly in the Trogarzo roll-out and I am sure there is a lot of tweaking to the marketing effort there. Theya re looking for a new marketing person. They are preparing for entering Europe with Trogarzo (maybe more?). They are preparing for the re-launch of Egrifta if the F4 is approved. There is a lot on their plates at the moment. This raises risks related to executing well on all fo these matters, but I think they can handle it.